LOS ANGELES - Aadi Bioscience, Inc. (NASDAQ: AADI), a precision oncology company, has announced the discontinuation of its PRECISION1 trial for nab-sirolimus, a treatment for solid tumors with specific genetic alterations. The Independent Data Monitoring Committee found that the trial would not meet the efficacy threshold required for accelerated approval. The company will now concentrate on its commercial product, FYARRO®, for advanced malignant PEComa, a rare cancer type, which reported sales of $6.2 million in the second quarter.
Aadi also revealed plans to conserve cash by pausing new patient enrollment in ongoing Phase 2 trials for endometrial cancer and neuroendocrine tumors, while continuing treatment for those already enrolled. The company will reduce its R&D workforce by 80% to extend its cash runway until at least the second half of 2026.
David Lennon, President and CEO of Aadi Bioscience, expressed gratitude to all participants involved in the PRECISION1 trial and acknowledged the need for the company to focus on preserving cash and maximizing shareholder value. He mentioned that the full analysis of the trial would be shared at a later date.
The company's current focus is on the commercial success of FYARRO®, the sole preferred treatment for patients with advanced malignant PEComa. Aadi has also engaged an advisory firm to explore strategic options to enhance shareholder value.
The information contained in this article is based on a press release statement from Aadi Bioscience.
In other recent news, Aadi Bioscience announced its Q2 2024 financial results, which showed $6.2 million in FYARRO product sales for the quarter, marking a 15% increase from Q1. The company is also advancing its lead candidate, nab-sirolimus, in various clinical trials aimed at addressing mTOR-driven tumors. Aadi Bioscience ended the quarter with $78.6 million in cash, with expectations that these funds will sustain operations into the fourth quarter of 2025. Despite a significant net loss of $14.6 million for Q2, the company is optimistic about the potential of nab-sirolimus in various mTOR-driven tumors. Aadi Bioscience's leadership, including Loretta Itri and David Lennon, acknowledged the challenges in predicting response rates among neuroendocrine tumor subtypes but remains committed to exploring the efficacy and safety of nab-sirolimus in these conditions. These are the recent developments from Aadi Bioscience.
InvestingPro Insights
Aadi Bioscience, Inc. (NASDAQ: AADI) finds itself at a critical juncture after the discontinuation of the PRECISION1 trial. The company's strategic shift to preserve cash and focus on FYARRO® coincides with some noteworthy financial metrics and market performance. InvestingPro data reveals a market capitalization of $39.38 million, highlighting the company's relatively small size within the biotech industry. Despite facing challenges, AADI holds more cash than debt on its balance sheet, which aligns with their current cash conservation strategy.
According to InvestingPro Tips, while AADI is quickly burning through cash, it is worth noting that analysts have revised their earnings upwards for the upcoming period, indicating potential optimism in the company's financial prospects. Additionally, AADI's liquid assets exceed its short-term obligations, providing it with a buffer to manage near-term financial commitments. However, analysts do not anticipate the company to be profitable this year, and the valuation implies a poor free cash flow yield, reflecting the company's current financial strain and the need for strategic maneuvers to improve its financial standing.
Investors may also find interest in AADI's price performance. The stock has experienced a significant return over the last week, with an 11.43% price total return, which could be a sign of market reaction to recent corporate developments or broader market movements. Yet, it's important to consider that the price has fallen significantly over the last year, with a one-year price total return of -73.24%. This volatility underscores the importance of keeping informed on the latest market trends and company-specific news.
For those looking to delve deeper into AADI's financial health and market potential, additional InvestingPro Tips are available, providing a more comprehensive analysis of the company. With investment decisions hinging on the latest data and expert insights, accessing the full range of tips on InvestingPro could be invaluable. Currently, there are 10 additional InvestingPro Tips listed for AADI, which can be explored for a more detailed investment perspective.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.